APOE and Alzheimer disease: Compared with a fused peptide which may have shorter half-life [44,45], the remarkable lipid binding and LDLR binding avidity of the apoE4-(72-166) suggests the possible feasibility for designing a competitive peptide against atherosclerosis or AD.